The Evolution of S100B Inhibitors for the Treatment of Malignant Melanoma

Overview

Journal Future Med Chem

Specialties Chemistry
Pharmacy

Date 2012 Dec 22

PMID 23256816

Citations 28

Authors

Kira G Hartman

Laura E McKnight

Melissa A Liriano

David J Weber

Affiliations

Soon will be listed here.

Abstract

Malignant melanoma continues to be an extremely fatal cancer due to a lack of viable treatment options for patients. The calcium-binding protein S100B has long been used as a clinical biomarker, aiding in malignant melanoma staging and patient prognosis. However, the discovery of p53 as a S100B target and the consequent impact on cell apoptosis redirected research efforts towards the development of inhibitors of this S100B-p53 interaction. Several approaches, including computer-aided drug design, fluorescence polarization competition assays, NMR, x-ray crystallography and cell-based screens have been performed to identify compounds that block the S100B-p53 association, reactivate p53 transcriptional activities and induce cancer cell death. Eight promising compounds, including pentamidine, are presented in this review and the potential for future modifications is discussed. Synthesis of compound derivatives will likely exhibit increased S100B affinity and mimic important S100B-target dynamic properties that will result in high specificity.

Citing Articles

Extract Ameliorates Melanoma Cell Proliferation and Invasion into Mouse Lungs by Suppressing PAX3 Expression.

Hiramoto K, Oikawa H Int J Mol Sci. 2024; 25(23).

PMID: 39684511 PMC: 11640897. DOI: 10.3390/ijms252312800.

Deficiency Reduces Proliferation, Increases Apoptosis, and Alters Secretion in Enteric Glial Cells of Mouse Small Intestine in Culture.

Teramoto H, Hirashima N, Tanaka M Cells. 2023; 12(14).

PMID: 37508531 PMC: 10378349. DOI: 10.3390/cells12141867.

The S100B Protein: A Multifaceted Pathogenic Factor More Than a Biomarker.

Michetti F, Clementi M, Di Liddo R, Valeriani F, Ria F, Rende M Int J Mol Sci. 2023; 24(11).

PMID: 37298554 PMC: 10253509. DOI: 10.3390/ijms24119605.

CRISPR/dCas9-KRAB-Mediated Suppression of Restores p53-Mediated Apoptosis in Melanoma Cells.

Roy Choudhury S, Heflin B, Taylor E, Koss B, Avaritt N, Tackett A Cells. 2023; 12(5).

PMID: 36899866 PMC: 10000373. DOI: 10.3390/cells12050730.

S100B Protein as a Therapeutic Target in Multiple Sclerosis: The S100B Inhibitor Arundic Acid Protects from Chronic Experimental Autoimmune Encephalomyelitis.

Camponeschi C, Carluccio M, Amadio S, Clementi M, Sampaolese B, Volonte C Int J Mol Sci. 2021; 22(24).

PMID: 34948360 PMC: 8708367. DOI: 10.3390/ijms222413558.

References

Arkenau H, Kefford R, Long G . Targeting BRAF for patients with melanoma. Br J Cancer. 2010; 104(3):392-8. PMC: 3049553. DOI: 10.1038/sj.bjc.6606030. View

Markowitz J, MacKerell Jr A, Weber D . A search for inhibitors of S100B, a member of the S100 family of calcium-binding proteins. Mini Rev Med Chem. 2007; 7(6):609-16. DOI: 10.2174/138955707780859422. View

Guvench O, MacKerell Jr A . Computational fragment-based binding site identification by ligand competitive saturation. PLoS Comput Biol. 2009; 5(7):e1000435. PMC: 2700966. DOI: 10.1371/journal.pcbi.1000435. View

Moore B . A soluble protein characteristic of the nervous system. Biochem Biophys Res Commun. 1965; 19(6):739-44. DOI: 10.1016/0006-291x(65)90320-7. View

Baudier J, Cole R . Interactions between the microtubule-associated tau proteins and S100b regulate tau phosphorylation by the Ca2+/calmodulin-dependent protein kinase II. J Biol Chem. 1988; 263(12):5876-83. View

Liriano M, Varney K, Wright N, Hoffman C, Toth E, Ishima R . Target binding to S100B reduces dynamic properties and increases Ca(2+)-binding affinity for wild type and EF-hand mutant proteins. J Mol Biol. 2012; 423(3):365-85. PMC: 3462298. DOI: 10.1016/j.jmb.2012.07.011. View

Wilder P, Baldisseri D, Udan R, Vallely K, Weber D . Location of the Zn(2+)-binding site on S100B as determined by NMR spectroscopy and site-directed mutagenesis. Biochemistry. 2003; 42(46):13410-21. DOI: 10.1021/bi035334q. View

Steiner J, Bogerts B, Schroeter M, Bernstein H . S100B protein in neurodegenerative disorders. Clin Chem Lab Med. 2011; 49(3):409-24. DOI: 10.1515/CCLM.2011.083. View

Donato R . S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. Int J Biochem Cell Biol. 2001; 33(7):637-68. DOI: 10.1016/s1357-2725(01)00046-2. View

10.

Wright N, Inman K, Levine J, Cannon B, Varney K, Weber D . Refinement of the solution structure and dynamic properties of Ca(2+)-bound rat S100B. J Biomol NMR. 2008; 42(4):279-86. PMC: 2804984. DOI: 10.1007/s10858-008-9282-y. View

11.

Raman E, Yu W, Guvench O, MacKerell A . Reproducing crystal binding modes of ligand functional groups using Site-Identification by Ligand Competitive Saturation (SILCS) simulations. J Chem Inf Model. 2011; 51(4):877-96. PMC: 3090225. DOI: 10.1021/ci100462t. View

12.

Riuzzi F, Sorci G, Donato R . S100B stimulates myoblast proliferation and inhibits myoblast differentiation by independently stimulating ERK1/2 and inhibiting p38 MAPK. J Cell Physiol. 2006; 207(2):461-70. DOI: 10.1002/jcp.20580. View

13.

Foster T, MacKerell Jr A, Guvench O . Balancing target flexibility and target denaturation in computational fragment-based inhibitor discovery. J Comput Chem. 2012; 33(23):1880-91. PMC: 3438888. DOI: 10.1002/jcc.23026. View

14.

Flaherty K, Puzanov I, Kim K, Ribas A, McArthur G, Sosman J . Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010; 363(9):809-19. PMC: 3724529. DOI: 10.1056/NEJMoa1002011. View

15.

Berking C, Schlupen E, Schrader A, Atzpodien J, Volkenandt M . Tumor markers in peripheral blood of patients with malignant melanoma: multimarker RT-PCR versus a luminoimmunometric assay for S-100. Arch Dermatol Res. 1999; 291(9):479-84. DOI: 10.1007/s004030050441. View

16.

Zimmer D, Cornwall E, Landar A, Song W . The S100 protein family: history, function, and expression. Brain Res Bull. 1995; 37(4):417-29. DOI: 10.1016/0361-9230(95)00040-2. View

17.

Marenholz I, Heizmann C, Fritz G . S100 proteins in mouse and man: from evolution to function and pathology (including an update of the nomenclature). Biochem Biophys Res Commun. 2004; 322(4):1111-22. DOI: 10.1016/j.bbrc.2004.07.096. View

18.

Arcuri C, Bianchi R, Brozzi F, Donato R . S100B increases proliferation in PC12 neuronal cells and reduces their responsiveness to nerve growth factor via Akt activation. J Biol Chem. 2004; 280(6):4402-14. DOI: 10.1074/jbc.M406440200. View

19.

Castets F, Griffin W, Marks A, Van Eldik L . Transcriptional regulation of the human S100 beta gene. Brain Res Mol Brain Res. 1997; 46(1-2):208-16. DOI: 10.1016/s0169-328x(96)00298-7. View

20.

Baudier J, Delphin C, Grunwald D, Khochbin S, Lawrence J . Characterization of the tumor suppressor protein p53 as a protein kinase C substrate and a S100b-binding protein. Proc Natl Acad Sci U S A. 1992; 89(23):11627-31. PMC: 50606. DOI: 10.1073/pnas.89.23.11627. View